{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:20:45Z","timestamp":1790774445094,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1097\/wnf.0b013e31806450da","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T02:09:17Z","timestamp":1236218957000},"page":"25-33","source":"Crossref","is-referenced-by-count":40,"title":["Bexarotene as Add-On to Antipsychotic Treatment in Schizophrenia Patients"],"prefix":"10.1097","volume":"31","author":[{"given":"Vladimir","family":"Lerner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanoch","family":"Miodownik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly","family":"Gibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekateryna","family":"Kovalyonok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Shleifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann B.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ritsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.1073\/pnas.91.16.7772","article-title":"High level of a retinoic acid-generating dehydrogenase in the meso telencephalic dopamine system.","volume":"91","author":"McCaffery","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1095\/biolreprod46.5.802","article-title":"Developmental changes in endogenous retinoids during pregnancy and embryogenesis in the mouse.","volume":"46","author":"Satre","year":"1992","journal-title":"Biol Reprod"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/cercor\/12.12.1244","article-title":"Retinoic acid synthesis in the postnatal mouse brain marks distinct developmental stages and functional systems.","volume":"12","author":"Wagner","year":"2002","journal-title":"Cereb Cortex"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/hmg\/6.4.577","article-title":"A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia.","volume":"6","author":"Arinami","year":"1997","journal-title":"Hum Mol Genet"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1194\/jlr.R100015-JLR200","article-title":"Gene expression regulation by retinoic acid.","volume":"43","author":"Balmer","year":"2002","journal-title":"J Lipid Res"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"14349","DOI":"10.1073\/pnas.94.26.14349","article-title":"Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family.","volume":"94","author":"Samad","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1073\/pnas.95.13.7240","article-title":"Three independent lines of evidence suggest retinoids as causal to schizophrenia.","volume":"95","author":"Goodman","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.mp.4001668","article-title":"Microarray results suggest altered transport and lowered synthesis of retinoic acid in schizophrenia.","volume":"10","author":"Goodman","year":"2005","journal-title":"Mol Psychiatry"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0166-4328(03)00099-8","article-title":"Vitamin A deficiency and relational memory deficit in adult mice: relationships with changes in brain retinoid signalling.","volume":"145","author":"Etchamendy","year":"2003","journal-title":"Behav Brain Res"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"11714","DOI":"10.1073\/pnas.191369798","article-title":"Vitamin deprivation results in reversible loss of hippocampal long-term synaptic plasticity.","volume":"98","author":"Misner","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1530-0277.2001.tb02154.x","article-title":"A retinoic acid receptor antagonist suppresses brain retinoic acid receptor overexpression and reverses a working memory deficit induced by chronic ethanol consumption in mice.","volume":"25","author":"Alfos","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"key":"R14-4-20210203","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1460-9568.2004.03563.x","article-title":"Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain.","volume":"20","author":"Corcoran","year":"2004","journal-title":"Eur J Neurosci"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1073\/pnas.0437937100","article-title":"Evidence for defective retinoid transport and function in late onset Alzheimer's disease.","volume":"100","author":"Goodman","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pneurobio.2005.03.002","article-title":"Role of retinoid signalling in the adult brain.","volume":"75","author":"Lane","year":"2005","journal-title":"Prog Neurobiol"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1073858404263520","article-title":"Retinoic acid signaling in the nervous system of adult vertebrates.","volume":"10","author":"Mey","year":"2004","journal-title":"Neuroscientist"},{"key":"R18-4-20210203","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1021\/jm00044a014","article-title":"Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids.","volume":"37","author":"Boehm","year":"1994","journal-title":"J Med Chem"},{"key":"R19-4-20210203","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/jnci\/91.24.2118","article-title":"Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.","volume":"91","author":"Bischoff","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R20-4-20210203","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1200\/JCO.2003.05.068","article-title":"Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.","volume":"21","author":"Esteva","year":"2003","journal-title":"J Clin Oncol"},{"key":"R21-4-20210203","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJM199009203231205","article-title":"Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.","volume":"323","author":"Hong","year":"1990","journal-title":"N Engl J Med"},{"key":"R22-4-20210203","first-page":"514","article-title":"Bexarotene ligand pharmaceuticals.","volume":"1","author":"Hurst","year":"2000","journal-title":"Curr Opin Investig Drugs"},{"key":"R23-4-20210203","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1200\/JCO.2001.19.10.2626","article-title":"Multi-institutional phase I\/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.","volume":"19","author":"Khuri","year":"2001","journal-title":"J Clin Oncol"},{"key":"R24-4-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1440-0960.2001.00488.x","article-title":"Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials.","volume":"42","author":"Prince","year":"2001","journal-title":"Australas J Dermatol"},{"key":"R25-4-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/1381612003401415","article-title":"Therapeutic applications for ligands of retinoid receptors.","volume":"6","author":"Thacher","year":"2000","journal-title":"Curr Pharm Des"},{"issue":"Suppl 1","key":"R27-4-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000248878","article-title":"Mucocutaneous and systemic toxicity of retinoids: monitoring and management.","volume":"175","author":"Shalita","year":"1987","journal-title":"Dermatologica"},{"key":"R29-4-20210203","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R30-4-20210203","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000285058","article-title":"Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group.","volume":"30","author":"White","year":"1997","journal-title":"Psychopathology"},{"key":"R31-4-20210203","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS).","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr Res"},{"key":"R34-4-20210203","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"Suppl 1","key":"R36-4-20210203","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"R37-4-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001504-200503000-00011","article-title":"Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics.","volume":"18","author":"Rettenbacher","year":"2005","journal-title":"Curr Opin Psychiatry"},{"key":"R38-4-20210203","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.yic.0000224786.75664.3b","article-title":"Early changes of plasma lipids during treatment with atypical antipsychotics.","volume":"21","author":"Rettenbacher","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R39-4-20210203","first-page":"77","article-title":"Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients.","volume":"40","author":"Conley","year":"2007","journal-title":"Psychopharmacol Bull"},{"key":"R40-4-20210203","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1389557023406223","article-title":"Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.","volume":"2","author":"Njar","year":"2002","journal-title":"Mini Reviews Med Chem"},{"key":"R41-4-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4088\/JCP.v66n0111","article-title":"Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine.","volume":"66","author":"Kelly","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R42-4-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.brainresrev.2005.10.001","article-title":"Thyroid hormones and retinoids: a possible link between genes and environment in schizophrenia.","volume":"51","author":"Palha","year":"2006","journal-title":"Brain Res Rev"},{"key":"R43-4-20210203","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/jcp.20784","article-title":"Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease.","volume":"209","author":"Goodman","year":"2006","journal-title":"J Cell Physiol"},{"key":"R44-4-20210203","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature03711","article-title":"Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.","volume":"436","author":"Yang","year":"2005","journal-title":"Nature"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-200801000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:57:20Z","timestamp":1786039040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200801000-00004"}},"subtitle":["A Pilot Open-Label Trial"],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31806450da","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}